phosphatidylinositol transfer protein membrane associated 2Genealiases: NIR-3 · NIR3 · RDGB2 · RDGBA2
Q-omics provides the consensus-scored PITPNM2 profile across patient tissues and cancer cell-line models. PITPNM2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PITPNM2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PITPNM2 protein abundance shows 19,759 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where PITPNM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITPNM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITPNM2 survival associations across molecular data types. PITPNM2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITPNM2 RNA expression–survival associations across cancer types. High PITPNM2 expression shows unfavorable associations in ACC, UVM and MESO, but favorable associations in SCLC, UCS and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PITPNM2 RNA expression.
This table summarizes PITPNM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PITPNM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITPNM2 shows lower tumor expression in THCA, LUAD, BLCA and KICH and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PITPNM2 RNA expression in tumor versus normal tissue (log2 FC = +0.960, t-test p < 0.001).
This table shows molecular features associated with PITPNM2 in patient tissues and cancer cell lines. In patient samples, PITPNM2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PITPNM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
